Lupus & antiphospholipid syndrome
Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico
Authors' conclusion
In our group of SLE patients, 5.7% had a disease flare after SARS-CoV-2 mRNA vaccination. Most had exacerbations involving major organs/systems. Mucocutaneous manifestations, anti-Ro antibodies, disease activity, and corticosteroids were associated with flares.
Study context
- Population
- Puerto Ricans with systemic lupus erythematosus (SLE) who received mRNA COVID-19 vaccines
- Participants
- 247 participants
- Exposure
- SLE patients with vs without exacerbation after SARS-CoV-2 mRNA vaccination
- Post-vaccination exacerbationn = 14
- Outcome
- Post-vaccination SLE exacerbation (impact of SARS-CoV-2 mRNA vaccination on clinical course of SLE)
Main finding
As reported in the abstract
Post-vaccination exacerbation
5.7%
14
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Major organ involvement among patients with post-vaccination flares | Post-vaccination flares 71.4% |
Baseline factors associated with post-vaccination flares
- Photosensitivity, oral ulcers, anti-Ro antibodies, higher Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and corticosteroids exposure were associated with post-vaccination flares
Mean SLEDAI, ED visits, hospitalisations, disease damage and immunosuppressive drug exposure, before vs after vaccination
- No significant differences before and after SARS-CoV-2 mRNA vaccination
Disease control among patients with flares · 12 months
- All patients fully controlled without evidence of active disease
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →